The role of intravenous immunoglobulins in pediatric diseases

Indian Pediatrics

Volumn 36, Issue 1, 1999, Pages 51-63

  Ramasubramanian, K V ^a   Kumar, Amit ^a   Kabra, S K ^a   Seth, V ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANAPHYLAXIS; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; DERMATOMYOSITIS; DRUG EFFECT; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEWBORN INFECTION; POLYNEUROPATHY; REVIEW; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; CHILD; GUILLAIN-BARRE SYNDROME; HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INFANT, NEWBORN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEDIATRICS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 0032920316     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Dwyer JM. Immunogobulins in autoimmunity: History and mechanisms of action. Clin Exp Rheumatol 1996; 14 (Suppl 15): S3-S7.
2. Hill LE, Moltison PL. Hypogammaglobulinemia in the United Kingdom. 13. Conclusions. Medical Research Council Special Report Series No. 31, London, 1971; pp 124-127.
3. Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994; 57: S6-S8.
4. Mouthon L, Kaveri SV, Spalter SH, Desmazes L, Lefranc C, Desai R, et al. Mechanism of action of IVIG in immune-mediated diseases. Clin Exp Immunol 1996; 104 (Suppl 1): 3-9.
5. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine DM, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use. Clin Exp Immunol 1993; 92: 369-372.
6. Hurez V, Kaveri SV, Mouthob A, Dietrich G, Mani JC, Klatzmann D, et al. Anti CD4 activity of normal human immunoglobulins for therapeutic use (IVIG). Therap Immunol 1994; 1: 269-278.
7. Sullivan KM, Kopecky Kg, Jocom J, Fisher L, Buckner CD, Meyers DJ, et al. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-709.
8. Dietrich G, Varela F, Hurez V, Bounamin M, Kazatchkine MD. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993; 23: 2945-2950.
9. Mankarious S, Lee M, Fisher S, Pyun KH, Ochs HD, Oxelins VA, et al. The half lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988; 112: 634-640.
10. Hayney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 1994; 97 (Suppl 1): 11-15.
11. WHO Scientific Group. Primary immunodefiency diseases. Immunodeficiency Rev 1992; 3: 195-236.
12. Hermaszewski RA, Webster ADB. Primary hypogammaglobulinemia: A survey of clinical manifestations and complications. Quart J Med 1993; 86: 31-42.
13. Chapel HM. Consensus panel for the diagnosis and management of primary antibody deficiencies. Consensus on diagnosis and management of primary antibody deficiencies. Br Med J 1994; 308: 581-585.
14. Gardulf A, Hammarstorm L, Smith CIE. Home treatment of hypogammaglobuli-nemia with subcutaneous immunoglobulin by rapid infusion. Lancet 1991; 338: 162-166.
15. Jenkins M. Human immunodeficiency virus type 1 infection in infants and children. In: Rudolph's Pediatrics, 20th edn. Eds. Rudolph AM, Hoffman JIE, Rudolph CD. Connecticut: Appleton and Lange 1996; pp 660-661.
16. Delia M, Hernandez R. Scott GB. HIV infection. In: Gellins and Kagan's Current Pediatrie Therapy, 15th edn. Eds. Burg FD, Ingelfinger JR, Wald ER, Polkin RA. Philadelphia, W.B. Saunders Co, 1996; pp 645-651.
17. Mofenson M, John Moye JR, Korelitz J, Bethel J, Hirschhorn R, Nugent R, et al. Cross over of placebo patients to intravenous immunoglobulin confirms the efficacy for prophylaxis of bacterial infections and reduction of hospitalization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13: 477-484.
18. Leung DYM. Kawasaki Syndrome: Immunomodulatory benefit and potential toxin neutralization by intravenous immunoglobulin. Clin Exp Immunol 1996; 104 (Suppl 1): 49-54.
19. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Fernen P, Freed M. et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87: 1776-1780.
20. Sundel RP, Newberger JW. Kawasaki Syndrome. In: Gellins and Kagan's Current Pediatric Therapy, 15th edn. Eds. Burg FD, Ingelfinger JR, Wald ER, Polkin RA. Philadelphia, W.B. Saunders Co, 1996; pp 195-197.
21. Manco-Johnson MJ. Hemostasis and Bleeding Disorders. In: Rudolph's Pediatrics, 20th edn. Eds. Rudolph AM, Hoffman JIE, Rudolph CD. Connecticut, Appleton and Lange, 1996; pp 1241-1242.
22. Blanchette VS, Luke B, Andrew M. Sommerville-Nielsen S, Barnard D, Barrie D Veber, et al. A prospective randomized trial of high-dose intravenous immune globulin g therapy, oral prednisone therapy and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-995.
23. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; ii: 464-468.
24. Bussel JB, Goldman A, Imbach P, Schulman I, Hilgartner MW. Treatment of acute ITP in childhood with intravenous infusion of gammaglobulin. J Pediatr 1985; 106: 886-890.
25. Hara T, Sochida Miyazaki N, Goya N. High dose gammaglobulin and methylprednisolone therapy for idiopathic thrombocyto-penic purpura in children. Eur J Pediatr 1985; 144: 240-242.
26. Haslam RHA. The polyradiculopathies In: Gellins and Kagan's Current Pediatric Therapy, 15th edn. Eds. Burg FD, Ingelfinger JR, Wald ER, Polkin RA. Philadelphia, W.B. Saunders Co, 1996; pp 71-73.
27. Van der Meche FGA. The Guillain-Barre Syndrome: Plasma exchange or immunoglobulins intravenously. J Neurol Nerosurg Psychiatry 1994; 57 (Suppl): 33-34.
28. Ouvrier R, Rapin I. Childhood neuropathies. In: Rodolph's Pediatrics, 20th edn. Eds. Rudolph AM, Hoffman JIE, Rudolph CD. Connecticut Appleton and Lange, 1996; p 1972.
29. French Co-operative Group on Plasma Exchange in Guillain-Barre Syndrome. Efficacy of plasma exchange in Guillain-Barre syndrome: Role of replacement therapies. Ann Neurol 1987; 22: 753-761.
30. Van Der Meche FGA, Schmitz PIM, Dutch Guillain-Barre Study Group. A randomized controlled trial comparing intravenous immunoglobulin and plasma exchange in Guillainbarre syndrome. N Eng J Med 1992; 326: 1123-1129.
31. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin and combined treatment in Guillain Barre Syndrome. Lancet 1997; 349: 225-230.
32. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered .immune serum globulin in patients with Guillain-Barre Syndrome. J Pediatr 1990; 116: 141-144.
33. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre syndrome with high dose immuneglobulins combined with methyl prednisolone: A pilot study. Ann Neurol 1994; 35: 749-752.
34. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Doube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyneuropathy more than no treatment. Ann Neurol 1982; 11: 136-141.
35. A Van Doorn PA. Intravenous immuneglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1994; 57 (Suppl): 38-42.
36. Dyck PJ, Daube J, O'Brien PC, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyneuropathy. N Engl J Med 1986; 314: 461-465.
37. Miller LC, Tucker LB, Schaller JG. Dermatomyositis and polymyositis. In: Gellins and Kagan's Current Pediatric Therapy, 15th edn. Eds. Burg FD, Ingelfinger JR, Wald ER, Polkin RA, Philadelphia, W.B. Saunders Co, 1996; pp 386-387.
38. Cherin P, Herson S, Wechsler S, Piette J, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and derma-myositis: An open study with 20 adult patients. Am J Med 1991; 91: 162-168.
39. Dalakas M, Illa I, Dambrosia JM, Soveidan AS, stein PD, Otero C, et al. A controlled trial of high dose intravenous immunoglobulin infusion as treatment for derma-myositis. N Engl J Med 1993; 329: 1993-2000.
40. Bass EB, Powe NR, Goodmann SN, Graziano SL, Griffiths RI, Kichler TS, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta analysis. Bone Marrow Transplant 1993; 12: 273-282.
41. Lacy JB, Ohlson A. Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: Meta-analysis. Arch Dis Child 1995; 72: F151-F155.
42. Maier WP, Gordon DS, Howard RF, Soleb MN, Miller SB, Liberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematoses-associated thrombocytopenia. Arthritis Rheum 1990; 33: 1233-1239.
43. Palla R, Cirami C, Bionda A, Marchitiello M. High dose intravenous gammaglobulin for membraneous nephropathy. Clin Nephrol 1986; 26: 314.
44. Drucker NA, Colan SD, Lewis AB, Bieser AS, Wessel DL, Takahashi AM, et al. y-Globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257.
45. Gajdos P. Intravenous immunoglobulin in myasthenia gravis. Clin Exp Immunol 1994; 97: S45-S51.
46. Bussel JB, Cunnigham-Rundler C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose of gammaglobulin. Vox Sang 1986; 51: 264-269.
47. IUIS/WHO Report. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an IUIS/WHO meeting. Bull World Health Organ 1982; 60: 43-47.
48. Weisman LE. The safety of intravenous immunoglobulin preparations. Isr J Med Sci 1994; 30: 459-463.
49. Roomer J, Morgenthaler JJ Scherz R, Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. Vox Sang 1982; 42: 62-73.
50. Taketoma CK, Hodding JH, Kraus DM. Immune Globulin intravenous. In: Pediatric Dosage Handbook, 3rd edn. Cleveland, Lexi-Comp Inc, 1996-97; p 367.
51. NIH Consensus Conference. Intravenous immune globulin: Prevention and treatment of disease. JAMA 1990; 264: 3189-3193.
52. Nydegger UE. Safety and side effects of intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996; 14: S53-S57.
53. McCluskey DR, Boyd NA. Anaphylaxis with intravenous immunoglobulin. Lancet 1990; 336: 874.